Abstract

The hemoglobin degradation process in Plasmodium parasites is vital for nutrient acquisition required for their growth and proliferation. In P. falciparum, falcipains (FP-2 and FP-3) are the major hemoglobinases, and remain attractive antimalarial drug targets. Other Plasmodium species also possess highly homologous proteins to FP-2 and FP-3. Although several inhibitors have been designed against these proteins, none has been commercialized due to associated toxicity on human cathepsins (Cat-K, Cat-L and Cat-S). Despite the two enzyme groups sharing a common structural fold and catalytic mechanism, distinct active site variations have been identified, and can be exploited for drug development. Here, we utilize in silico approaches to screen 628 compounds from the South African natural sources to identify potential hits that can selectively inhibit the plasmodial proteases. Using docking studies, seven abietane diterpenoids, binding strongly to the plasmodial proteases, and three additional analogs from PubChem were identified. Important residues involved in ligand stabilization were identified for all potential hits through binding pose analysis and their energetic contribution determined by binding free energy calculations. The identified compounds present important scaffolds that could be further developed as plasmodial protease inhibitors. Previous laboratory assays showed the effect of the seven diterpenoids as antimalarials. Here, for the first time, we demonstrate that their possible mechanism of action could be by interacting with falcipains and their plasmodial homologs. Dynamic residue network (DRN) analysis on the plasmodial proteases identified functionally important residues, including a region with high betweenness centrality, which had previously been proposed as a potential allosteric site in FP-2.

Highlights

  • The implementation of artemisinin-based combination therapy (ACT) as the first line drug in the treatment of uncomplicated malaria cases has led to a substantial reduction in the global malaria burden in recent years [1]

  • Important residues involved in ligand stabilization were identified for all potential hits through binding pose analysis and their energetic contribution determined by binding free energy calculations

  • Dynamic residue network (DRN) analysis on the plasmodial proteases identified functionally important residues, including a region with high betweenness centrality, which had previously been proposed as a potential allosteric site in FP-2

Read more

Summary

Introduction

The implementation of artemisinin-based combination therapy (ACT) as the first line drug in the treatment of uncomplicated malaria cases has led to a substantial reduction in the global malaria burden in recent years [1]. With recent disease surveillance reports indicating the development and spread of plasmodia strains with ACT drug resistance in South East Asia, the current combined efforts towards malaria control and elimination could be derailed [2,3,4,5]. While this is an anticipated phenomenon considering the parasite’s inherent ability of overcoming the therapeutic effect of almost all known antimalarial drugs [6,7], a major health concern remains how global disease control systems. The search for generation antimalarial drugs that can interrupt essential molecular pathways, crucial for parasite growth and multiplication, remains a top priority

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call